Daniel Kline, MD
Ophthalmology · Irvine, CANPI 1861561276
Payments from drug & device makers
Across 126 payments — averaging $367.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$40K
- Glaukos Corporation$2K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$932
- Bausch & Lomb Americas Inc.$301
- Amgen$243
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$1,00016%
- Food & beverage$5,21583%
- Gifts$391%
- Entertainment$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $40,136 |
| Glaukos Corporation | 13 | $1,632 |
| Alcon | 20 | $1,314 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $932 |
| Bausch & Lomb Americas Inc. | 8 | $301 |
| Amgen(2 entities) | 7 | $243 |
| AbbVie(2 entities) | 10 | $221 |
| Kala Pharmaceuticals, Inc. | 4 | $190 |
| Sight Sciences, Inc. | 1 | $156 |
| Novartis | 6 | $130 |
| Avedro Inc. | 1 | $126 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $106 |
| Aerie Pharmaceuticals, Inc. | 5 | $100 |
| Sun Pharmaceutical Industries Inc. | 3 | $86 |
| Harrow Eye, LLC | 3 | $86 |
| Thea Pharma Inc. | 4 | $82 |
| Lensar, Inc. | 1 | $76 |
| Optos, Inc. | 2 | $53 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Ivantis, Inc | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Oasis Medical, Inc. | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$408
- Tecnis IOL$352
- AcrySof IQ PanOptix$263
- OMNI(R) SURGICAL SYSTEM (US)$156
- AcrySof IQ PanOptix UV IOL$144
- Tecnis Simplicity$135
- SIMBRINZA$125
- Rocklatan$125
- Rhopressa$125
- TEPEZZA$123
- EYSUVIS$122
- iDose$112
- enVista MX60 IOL$105
How this compares
$46,285 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $80,957 |
| Cyclosporine | 52 | $34,430 |
| XiidraLifitegrast | 18 | $28,163 |
| LumiganBimatoprost | 54 | $25,770 |
| VyzultaLatanoprostene Bunod | 24 | $14,466 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $12,628 |
| Latanoprost | 769 | $7,982 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $5,942 |
| Brimonidine Tartrate | 103 | $5,738 |
| Prednisolone Acetate | 121 | $3,346 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 146 | $3,192 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 81 | $3,128 |
| Alphagan PBrimonidine Tartrate | 11 | $2,943 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 19 | $2,541 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $221 | $109,671148 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $301 | $42,62942 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $100 | $12,62830 claims |
| AlconSimbrinza | $1,314 | $5,94215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Irvine
- Eran DuzmanIrvine$2.4M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.